Basic Information
| LncRNA/CircRNA Name | BC200 |
| Synonyms | NA |
| Region | NA |
| Ensemble | ENSG00000236824 |
| Refseq | NR_001568 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Cisplatin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot |
| Sample | NSCLC tissues,cell line(H1299/DDP) |
| Expression Pattern | up-regulated |
| Function Description | Higher expression of BC200 was found in NSCLC tissues than that of adjacent normal tissues. |
| Pubmed ID | 30779077 |
| Year | 2019 |
| Title | LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway. |
External Links
| Links for BC200 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |